Compare Dollar Tree, Inc. (DLTR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Novo Nordisk A/S — how do they compare? Dollar Tree, Inc. trades at $129.78 (market cap $24.72B), while Novo Nordisk A/S trades at $46.96 (market cap $202.59B). The key difference: Novo Nordisk A/S is far larger — about 8.2× Dollar Tree, Inc.'s market cap, and Novo Nordisk A/S pays a 3.87% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals.
| DLTR | NVO | |
|---|---|---|
Market Cap | $24.72B | $202.59B |
Sector | Health | Health |
52-Week High | $141.21 | $63.98 |
52-Week Low | $85.04 | $35.29 |
Enterprise Value | $31.30B | $217.28B |
Dividend Yield | — | 3.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLTR trades at $129.53, up 1.15% today, with a bullish technical signal supported by moving averages and key resistance at $130. The company shows strong profitability with a 36.71% gross margin and 34.71% ROE, though 2025 net income was negative due to a $4.41B tax charge. Recent earnings beats and a $2.5B share buyback authorization highlight positive momentum, while analyst consensus is a Buy with a $126.69 price target.
Outlook is cautiously optimistic given earnings strength and shareholder returns, but risks include competitive pressures, tariff impacts on margins, and volatile consumer spending. The stock's valuation at a P/E of 20.64 appears reasonable if profit normalization continues in 2026.
Novo Nordisk (NVO) trades at $46.72, down 0.95% on the day, with a bearish technical signal. The company maintains strong profitability with 35.35% net income margin and 59.82% ROE, though recent earnings show mixed signals with Q2 2026 beating expectations but facing competitive pressures. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio increased to 22.54%.
The outlook remains cautiously optimistic given strong fundamentals and analyst consensus (57.9% buy ratings), but near-term headwinds include intense competition with Eli Lilly, pricing challenges, and pipeline setbacks. Long-term potential exists in the obesity care market and AI-driven drug development initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
